Hutchison China MediTech (Chi-Med): Director's Share Dealing

HONG KONG, CHINA--(Marketwired - November 01, 2016) - Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM)

Director's Share Dealing

London: Tuesday, November 1, 2016: Hutchison China MediTech Limited ("Chi-Med") (NASDAQ: HCM) (AIM: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, sold 10,000 ordinary shares of US$1.00 each in Chi-Med (the "Ordinary Shares") at an average price of GBP18.453305 per share between October 24, 2016 and October 28, 2016 under a personal share trading plan (the "Plan"). Pursuant to the Plan, a total of 20,000 Ordinary Shares will be sold between October 24, 2016 and November 23, 2016 (inclusive). The Plan (and the previous sale of 15,000 Ordinary Shares made by Mr Howell on October 7, 2016) has been put in place to facilitate financial settlement arising from a marital separation agreement.

Following the above sale of 10,000 Ordinary Shares, the holding of Mr Howell is 128,600 Ordinary Shares, representing approximately 0.21% of the current issued share capital of Chi-Med.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1  Details of the person discharging managerial responsibilities/person     
   closely associated                                                       
a) Name                          Mr Michael Howell                          
                                                                            
2  Reason for the notification                                              
a) Position/status               Independent Non-executive Director of Chi- 
                                 Med                                        
b) Initial                       Initial notification                       
   notification/Amendment                                                   
                                                                            
3  Details of the issuer, emission allowance market participant, auction    
   platform, auctioneer or auction monitor                                  
a) Name                          Hutchison China MediTech Limited           
b) LEI                           N/A                                        
                                                                            
4  Details of the transaction(s): section to be repeated for (i) each type  
   of instrument; (ii) each type of transaction; (iii) each date; and (iv)  
   each place where transactions have been conducted                        
a) Description of the financial  Ordinary Shares of US$1.00 each            
   instrument, type of           DI ISIN: KYG4672N1016                      
   instrument                    ADS ISIN: US44842L1035                     
   Identification code                                                      
b) Nature of the transaction     Sale of 10,000 Ordinary Shares between     
                                 October 24, 2016 and October 28, 2016 at an
                                 average price of GBP18.453305              
                                 Price(s) Volume(s)                         
                                 GBP18.25 339                               
                                 GBP18.30 2,661                             
                                 GBP18.40 1,000                             
                                 GBP18.50 3,500                             
                                 GBP18.60 2,500                             
d) Aggregated information        Aggregated volume: 10,000                  
                                 Price information: GBP18.453305            
   - Aggregated volume                                                      
   - Price                                                                  
e) Date of the transaction       2016-10-24; 14:07 - disposal of 339        
                                 Ordinary Shares                            
                                 2016-10-25; 14:05 - disposal of 661        
                                 Ordinary Shares                            
                                 2016-10-25; 14:44 - disposal of 2,000      
                                 Ordinary Shares                            
                                 2016-10-25; 15:29 - disposal of 1,000      
                                 Ordinary Shares                            
                                 2016-10-26; 13:57 - disposal of 3,000      
                                 Ordinary Shares                            
                                 2016-10-28; 12:48 - disposal of 2,500      
                                 Ordinary Shares                            
                                 2016-10-28; 14:09 - disposal of 500        
                                 Ordinary Shares                            
f) Place of the transaction      London Stock Exchange (XLON)               
                                                                            

NOTES TO EDITORS
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

Contacts

Investor Enquiries                                                          
Christian Hogg, CEO  +852 2121 8200                                         
                                                                            
International Media                                                         
Enquiries                                                                   
Anthony Carlisle,    +44 7973 611 888  anthony.carlisle@cdrconsultancy.co.uk
Citigate Dewe        (Mobile)                                               
Rogerson                                                                    
                                                                            
U.S. Based Media                                                            
Enquiries                                                                   
Brad Miles, BMC      +1 (917) 570 7340 bmiles@bmccommunications.com         
Communications       (Mobile)                                               
                                                                            
Susan Duffy, BMC     +1 (917) 499 8887 sduffy@bmccommunications.com         
Communications       (Mobile)                                               
                                                                            
Investor Relations                                                          
Matt Beck, The Trout +1 (917) 415 1750 mbeck@troutgroup.com                 
Group                (Mobile)                                               
                                                                            
David Dible,         +44 7967 566 919  david.dible@citigatedr.co.uk         
Citigate Dewe        (Mobile)                                               
Rogerson                                                                    
                                                                            
Panmure Gordon (UK)                                                         
Limited                                                                     
Richard Gray /       +44 (20) 7886 2500                                     
Andrew Potts